Core Insights - Hologic (HOLX) is projected to hold over 18% of the global women's health devices market by 2025, with the market expected to grow at a CAGR of 10.2% from 2026 to 2035, driven by increasing gynecological disorders, preventive healthcare awareness, and demand for minimally invasive solutions [1][8] Company Performance - Hologic's GYN Surgical unit has shown consistent performance, with surgical revenues reaching $180.8 million in Q1 FY26, reflecting a 7.5% year-over-year increase in constant currency, primarily due to higher sales of MyoSure and Fluent devices, as well as the Gynesonics acquisition [2][8] - The company has expanded its business through internal product development and acquisitions, enhancing its sales network [2] Market Expansion - Hologic's investments in commercial and market access capabilities have significantly increased the reach of its minimally invasive surgical products, with MyoSure gaining more market share internationally than in the U.S., indicating strong demand in untapped markets for treatments of uterine polyps and fibroids [3] - The addition of the Acessa laparoscopic fibroid removal system complements MyoSure by addressing larger fibroids [3] - NovaSure has shown consistent double-digit international growth, and the Sonata system was added through the Gynesonics acquisition, allowing treatment of symptomatic uterine fibroids [4] Competitive Landscape - Hologic faces competition from Medtronic (MDT) and Johnson & Johnson (JNJ), both of which offer comprehensive surgical solutions [5] - Medtronic has recently launched its FDA-cleared Hugo robotic-assisted surgery system, expanding into gynecologic and general surgery procedures [5] - Johnson & Johnson's Surgery portfolio includes a variety of surgical products for open, laparoscopic, and robotic procedures, with recent launches in its aspiration-first stroke portfolio [6] Stock Performance and Valuation - Hologic shares have increased by 20.7% over the past year, contrasting with a 3.8% decline in the industry [7] - The stock is currently trading at a forward 12-month price-to-sales (P/S) ratio of 3.88X, which is above its median but lower than the industry average, and carries a Value Score of C [9]